本维莫德乳膏治疗斑块型银屑病的研究进展

谭 献¹, 郭 佳敏¹, 常 伟¹, 张 昕¹, 王 生²
1、华北理工大学附属唐山市工人医院 唐山 063000
2、通讯作者华北理工大学附属唐山市工人医院 唐山 063000

摘要

目的：斑块型银屑病是一种反复发作的、鳞屑斑块状皮肤病，其发病机制尚不完全清楚，目前无法治愈，这给患者的身心健康带来巨大挑战。研究表明，传统药物对斑块型银屑病治疗效果不佳，且不良反应较多。最新研究发现全球首创1类新型药物“本维莫德”通过抗炎、抗菌、抗氧化、诱导角质细胞分化等途径对银屑病发病机制起着关键作用，并且具有良好疗效和安全性。本文通过查阅相关文献，对本维莫德治疗银屑病的最新研究进展作一综述。

关键词

银屑病；本维莫德；芳香烃受体

参考

[1]全国银屑病流行调查组,邵长庚,张国威,等.全国1984年银屑病流行调查报告[J].皮肤病与性病,1989(01):60-72.[2]张建中.银屑病的流行病学与危险因素[J]．实用医院临床杂志，2013，10（1）：4一6.[3]Griffiths CEM, Armstrong AW, Gudjonsson JE,et al.Psoriasis[J]. Lancet.2021;397(10281):1301-1315.doi:10.1016/S0140-6736(20)32549-6[4]中华医学会皮肤性病学分会银屑病专业委员会.中国银屑病诊疗指南(2018完整版)[J].中华皮肤科杂志,2019(10):667-710.[5]张翰林,舒畅,晋红中.生物制剂治疗银屑病的研究进展[J].中国科学:生命科学,2021,51(08):1050-1059.[6]姚冬琴.全球首创新药本维莫德是如何诞生的[J].中国经济周刊,2019(14):37-39.[7]Lu ST, Kelly KA, Feldman SR. An overview of benvitimod for the treatment of psoriasis:a narrative review[J].Expert Opin Pharmacother. 2022;23(3):327-333. doi:10.1080/14656566.2021.2016699[8]Li J, Chen G, Wu H,et al.Identification of two pigments and a hydroxystilbene antibiotic from Photorhabdus luminescens[J]. Appl Environ Microbiol. 1995;61(12):4329-4333.doi:10.1128/aem.61.12.4329-4333.1995[9]Johnston A. Resolving Inflammation by Targeting an Ancient Innate Immune Sensor with a Bacterial Metabolite[J].J Invest Dermatol. 2017;137(10):2050-2052. doi:10.1016/j.jid.2017.07.815[10]Esser C, Rannug A. The aryl hydrocarbon receptor in barrier organ physiology,immunology, and toxicology[J]. Pharmacol Rev. 2015;67:259-279. doi:10.1124/pr.114.009001[11]Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans[J]. J Invest Dermatol.2017;137(10):2110-2119.doi:10. 1016/j.jid.2017.05.004[12]Mascanfroni ID, Takenaka MC, Yeste A, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α[J] . Nat Med, 2015, 2 1 (6 ) ：638 -646 .doi:10.1038/nm.3868[13]Napolitano M, Patruno C. Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin disease[J]. Med Hypotheses. 2018;116:96-100. doi:10.1016/j.mehy.2018.05.001[14]Furue M, Uchi H, Mitoma C, et al. Antioxidants for Healthy Skin: The Emerging Role of Aryl Hydrocarbon Receptors and Nuclear Factor-Erythroid 2-Related Factor-2[J]. Nutrients. 2017;9:223. doi:10.3390/nu9030223[15]中华医学会皮肤性病学分会银屑病学组.本维莫德乳膏治疗银屑病专家指导意见[J].中国皮肤性病学杂志,2021,35(6):707-710.DOI:10.13735/j.cjdv.1001-7089.202103186.[16]Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment[J]. Int J Mol Sci.2019;20(6):1475. doi:10.3390/ijms20061475[17]Stein Gold L, Bhatia N, Tallman AM, et al. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes[J]. J Am Acad Dermatol. 2021;84(3):624–631. doi:10.1016/j.jaad.2020.04.181[18]刘珉宇,于鹏霞,赵帅,等.苯烯莫德对实验性银屑病的治疗作用[J].中国新药与临床杂志,2016,35(08):589-595. DOI:10.14109/j.cnki.xyylc.2016.08.014.[19]Bissonnette R, Stein Gold L, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent[J]. J Am Acad Dermatol. 2021;84(4):1059-1067. doi:10.1016/j.jaad.2020.10.085[20]Kadam DP, Suryakar AN, Ankush RD,et al. Role of oxidative stress in various stages of psoriasis[J]. Indian J Clin Biochem. 2010;25:388-392. doi:10.1007/s12291-010-0043-9[21]Cai L, Chen GH, Lu QJ, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis[J].Chin Med J (Engl). 2020;133(24):2905-2909. doi:10.1097/CM9.0000000000001221[22]Chen L, Wu Y, Xiao B,et al. Application of benvitimod on psoriasis: A systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis [published online ahead of print, 2021Oct2][J].Therapie.2021; S0040-5957(21)00183-9.doi:10.1016/j.therap.2021.09.005[23]Paller AS, Stein Gold L, Soung J, et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis[J].J Am Acad Dermatol.2021;84(3):632-638. doi:10.1016/j.jaad.2020.05.135